Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05FGG
|
|||
| Former ID |
DCL000490
|
|||
| Drug Name |
Azilsartan
|
|||
| Synonyms |
TAK 536; TAK-536; Azilsartan (INN/USAN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H20N4O5
|
|||
| Canonical SMILES |
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
|
|||
| InChI |
1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)
|
|||
| InChIKey |
KGSXMPPBFPAXLY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 147403-03-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14784428, 14833581, 24127892, 44923423, 76847538, 85210070, 96025547, 103244284, 103951947, 128380015, 128380016, 134213509, 134348772, 134358743, 135203003, 136946516, 137229628, 139483677, 140904462, 144115313, 160645922, 162009745, 162172206, 162255215, 163686146, 164045364, 164216180, 164836101, 171578929, 172918178, 175265877, 175437730, 176247781, 178103483, 185979069, 189562169, 198993038, 210280800, 211534879, 223383337, 223573547, 223573548, 223659741, 223963167, 226529482, 241036926, 241377053, 249582132, 249617126, 251916420
|
|||
| ChEBI ID |
CHEBI:68850
|
|||
| ADReCS Drug ID | BADD_D00200 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin II receptor type-1 (AGTR1) | Target Info | Modulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Renin-angiotensin system | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Muscle/Heart Contraction | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Angiopoietin receptor Tie2-mediated signaling | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | ACE Inhibitor Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| Allograft Rejection | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6901). | |||
| REF 2 | Clinical pipeline report, company report or official report of Takeda. | |||
| REF 3 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.